Advertisement

Neoadjuvant Nab-Paclitaxel in Breast Cancer: Trial Results and Patient Care

The link between the achievement of pCR and the long-term clinical benefit was supported by findings of a pooled analysis, with the greatest prognostic value observed in aggressive tumor subtypes.

 The Lancet Oncology

click me